Podcast, Interview, Fireside Chat
E113: DOJ tries to break up Google, vaccine questions, Ukraine escalation & more
- The DOJ lawsuit against Google is projected to fail as judges are expected to deconstruct the case, though the agency's focus on ad brokering is considered misdirected compared to the true monopoly in search; Google's digital advertising share is expected to remain competitive while Amazon potentially captures 15 to 20% of the market in a few years.
- Legal strategies involving the unwinding of decade-old acquisitions are predicted to create market uncertainty, chill future deals, and damage U.S. competitiveness, while breaking up Google's advertising operations is expected to reduce publisher revenue by altering the auction model that currently yields 70 to 80% revenue shares.
- The removal of third-party cookies in 2024 and Apple's ID changes will severely impact tracking and retargeting capabilities, making revenue generation harder for publishers and networks, though emerging ad networks like Uber are projected to grow from $350 million to $1 billion in their second year within a dynamic, self-regulating market.
- Microsoft is expected to continue bundling products like Teams with Office to undercut independent competitors such as Slack, potentially forcing startups to exit or be acquired, prompting calls for transparency in Enterprise Licensing Agreements where individual product prices must sum to the bundle total to prevent cross-subsidization.
- Pfizer is expected to generate $10 to $15 billion from the vaccine this year, yet efficacy is predicted to wane quickly due to viral evolution, potentially necessitating boosters every two months; the risk of myocarditis in young people receiving the Moderna vaccine is estimated at 30 times higher relative to the baseline, though absolute incidence remains below 2 per 100,000.
- Scientific uncertainty remains regarding whether the spike protein persists in vaccinated individuals beyond a year, and public trust may decline if the vaccine's inability to stop transmission becomes widely perceived as overreach.
- The Biden administration is expected to continue escalating military support to Ukraine, including potential strikes on Crimea which carry risks of tactical nuclear use, as the conflict moves toward an endgame with a negotiated settlement uncertain within a two-to-10-year timeframe; Ukraine's reconstruction cost is estimated at $750 billion with Fitch Ratings projecting a path toward default.
- The aging research sector is driven by the "information theory of aging" supported by Harvard research, indicating epigenome degradation as the primary driver, with Yamanaka factors expected to extend mouse lifespans by 107% and human ex vivo clinical trials potentially launching within the next few years for specific tissues.
- Investors are anticipated to find opportunities over the next 10 years in backing teams likely to progress aging reversal clinical trials, although a complete reversal of aging for the entire human body to reach age 100 remains uncertain regarding the elimination of chronic conditions like Alzheimer's.